{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T21:21:42Z","timestamp":1773436902880,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Johnson & Johnson Innovative Medicine United States"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s13555-025-01353-x","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T02:54:32Z","timestamp":1739847272000},"page":"663-680","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Patient Disease Characteristics and Treatment Patterns in Mild\u2013Moderate Psoriasis: Results from Real-World Clinical Practice in the United States (PROSPECT Study)"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1480-040X","authenticated-orcid":false,"given":"Emily J.","family":"Goddard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4089-5809","authenticated-orcid":false,"given":"James M.","family":"Haughton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9093-0134","authenticated-orcid":false,"given":"James E.","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5604-1360","authenticated-orcid":false,"given":"Sophie G.","family":"Barlow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3441-1708","authenticated-orcid":false,"given":"Timothy P.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5492-1040","authenticated-orcid":false,"given":"Alexander M.","family":"Litvintchouk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4759-7955","authenticated-orcid":false,"given":"David","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"issue":"1","key":"1353_CR1","doi-asserted-by":"publisher","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","volume":"2","author":"JE Greb","year":"2016","unstructured":"Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016;2(1):16082.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"1353_CR2","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029\u201372.","journal-title":"J Am Acad Dermatol"},{"issue":"19","key":"1353_CR3","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360.","journal-title":"JAMA"},{"key":"1353_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.743180","volume":"8","author":"G Damiani","year":"2021","unstructured":"Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The Global, Regional, and National Burden of Psoriasis: results and insights from the Global Burden of Disease 2019 Study. Front Med (Lausanne). 2021;8: 743180.","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"1353_CR5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1046\/j.1087-0024.2003.09110.x","volume":"9","author":"J De Korte","year":"2004","unstructured":"De Korte J, Mombers FMC, Bos JD, Sprangers MAG. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc. 2004;9(2):140\u20137.","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"2","key":"1353_CR6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/jdv.16966","volume":"35","author":"NM Golbari","year":"2021","unstructured":"Golbari NM, van der Walt JM, Blauvelt A, et al. Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact. J Eur Acad Dermatol Venereol. 2021;35(2):417\u201321.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1353_CR7","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/bjd.18798","volume":"183","author":"R Villacorta","year":"2020","unstructured":"Villacorta R, Teeple A, Lee S, et al. A multinational assessment of work-related productivity loss and indirect costs from a survey of patients with psoriasis. Br J Dermatol. 2020;183(3):548\u201358.","journal-title":"Br J Dermatol"},{"key":"1353_CR8","unstructured":"World Health Organization. Global report on psoriasis. Geneva: WHO; 2016."},{"key":"1353_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115078","volume":"321","author":"L Liu","year":"2023","unstructured":"Liu L, Lin NX, Yu YT, et al. Epidemiology of mental health comorbidity in patients with psoriasis: an analysis of trends from 1986 to 2019. Psychiatry Res. 2023;321:115078.","journal-title":"Psychiatry Res"},{"issue":"1","key":"1353_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jaad.2019.08.026","volume":"82","author":"B Strober","year":"2020","unstructured":"Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82(1):117\u201322.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1353_CR11","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","volume":"84","author":"CA Elmets","year":"2021","unstructured":"Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84(2):432\u201370.","journal-title":"J Am Acad Dermatol"},{"key":"1353_CR12","unstructured":"US Food and Drug Administration. OTEZLA\u00ae (apremilast) tablets, for oral use 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/205437s011lbl.pdf. Accessed 11 Sept 24."},{"issue":"10","key":"1353_CR13","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","volume":"149","author":"AW Armstrong","year":"2013","unstructured":"Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States. JAMA Dermatol. 2013;149(10):1180.","journal-title":"JAMA Dermatol"},{"key":"1353_CR14","doi-asserted-by":"crossref","unstructured":"Korman N, Zhao Y, Pike J, Roberts J, Sullivan E. Patient satisfaction with current psoriasis treatment: a real-world study in the USA. Dermatol Online J. 2016;22(2):13030\/qt85t4348w.","DOI":"10.5070\/D3222030081"},{"issue":"11","key":"1353_CR15","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson P, Benford M, Harris N, Karavali M, Piercy J. Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand. Curr Med Res Opin. 2008;24(11):3063\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"1353_CR16","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","volume":"39","author":"P Anderson","year":"2023","unstructured":"Anderson P, Higgins V, Courcy J, et al. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on Disease Specific Programmes. Curr Med Res Opin. 2023;39(12):1707\u201315.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"1353_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux SM, Curtis B, Holbrook T, Milligan G, Piercy J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ Open. 2016;6(8):e010352.","journal-title":"BMJ Open"},{"key":"1353_CR18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","volume":"9","author":"V Higgins","year":"2016","unstructured":"Higgins V, Piercy J, Roughley A, et al. Trends in medication use in patients with type\u00a02 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes. 2016;9:371\u201380.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"4","key":"1353_CR19","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000250839","volume":"157","author":"T Fredriksson","year":"1978","unstructured":"Fredriksson T, Pettersson U. Severe psoriasis\u2013oral therapy with a new retinoid. Dermatologica. 1978;157(4):238\u201344.","journal-title":"Dermatologica"},{"key":"1353_CR20","doi-asserted-by":"crossref","unstructured":"EuroQol\u2014a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199\u2013208.","DOI":"10.1016\/0168-8510(90)90421-9"},{"issue":"8","key":"1353_CR21","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jval.2019.02.009","volume":"22","author":"AS Pickard","year":"2019","unstructured":"Pickard AS, Law EH, Jiang R, et al. United States valuation of EQ-5D-5L health states using an international protocol. Value Health. 2019;22(8):931\u201341.","journal-title":"Value Health"},{"issue":"3","key":"1353_CR22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210\u20136.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"1353_CR23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics"},{"key":"1353_CR24","unstructured":"US Department of Health and Human Services. Summary of the HIPAA Privacy Rule 2003. http:\/\/www.hhs.gov\/sites\/default\/files\/privacysummary.pdf. Accessed 11 Sept 24."},{"key":"1353_CR25","unstructured":"Health Information Technology (HITECH). Health Information Technology Act 2009. https:\/\/www.healthit.gov\/sites\/default\/files\/hitech_act_excerpt_from_arra_with_index.pdf. Accessed 11 Sept 24."},{"issue":"2","key":"1353_CR26","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/bjd.17403","volume":"181","author":"M Augustin","year":"2019","unstructured":"Augustin M, Sommer R, Kirsten N, et al. Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients. Br J Dermatol. 2019;181(2):358\u201365.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1353_CR27","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jaad.2017.03.037","volume":"77","author":"K Shah","year":"2017","unstructured":"Shah K, Mellars L, Changolkar A, Feldman SR. Real-world burden of comorbidities in US patients with psoriasis. J Am Acad Dermatol. 2017;77(2):287-92.e4.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1353_CR28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/2475530320970531","volume":"6","author":"M Tajalli","year":"2021","unstructured":"Tajalli M, Li T, Drucker AM, Qureshi AA, Cho E. A description of treatment patterns of psoriasis by medical providers and disease severity in US women. J Psoriasis Psoriatic Arthritis. 2021;6(1):45\u201351.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"1","key":"1353_CR29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s13555-016-0153-2","volume":"7","author":"AW Armstrong","year":"2017","unstructured":"Armstrong AW, Koning JW, Rowse S, et al. Under-treatment of patients with moderate to severe psoriasis in the United States: analysis of medication usage with health plan data. Dermatol Ther (Heidelb). 2017;7(1):97\u2013109.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1353_CR30","first-page":"213","volume":"12","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, Bellinato F, Maurelli M, et al. Reducing the risk of developing psoriatic arthritis in patients with psoriasis. Psoriasis (Auckl). 2022;12:213\u201320.","journal-title":"Psoriasis (Auckl)"},{"issue":"1","key":"1353_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","volume":"7","author":"O FitzGerald","year":"2021","unstructured":"FitzGerald O, Ogdie A, Chandran V, et al. Psoriatic arthritis. Nat Rev Dis Primers. 2021;7(1):59.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"1353_CR32","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s11136-020-02650-y","volume":"30","author":"R Jiang","year":"2021","unstructured":"Jiang R, Janssen MFB, Pickard AS. US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. Qual Life Res. 2021;30(3):803\u201316.","journal-title":"Qual Life Res"},{"issue":"5","key":"1353_CR33","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/ced.12841","volume":"41","author":"NJ Korman","year":"2016","unstructured":"Korman NJ, Zhao Y, Pike J, Roberts J. Relationship between psoriasis severity, clinical symptoms, quality of life and work productivity among patients in the USA. Clin Exp Dermatol. 2016;41(5):514\u201321.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"1353_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027535","volume":"9","author":"B Strober","year":"2019","unstructured":"Strober B, Greenberg JD, Karki C, et al. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. BMJ Open. 2019;9(4): e027535.","journal-title":"BMJ Open"},{"issue":"9","key":"1353_CR35","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.7326\/M22-1460","volume":"175","author":"LM DeTora","year":"2022","unstructured":"DeTora LM, Toroser D, Sykes A, et al. Good Publication Practice (GPP) guidelines for company-sponsored biomedical research: 2022 update. Ann Intern Med. 2022;175(9):1298\u2013304.","journal-title":"Ann Intern Med"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01353-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01353-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01353-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T08:04:19Z","timestamp":1741939459000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01353-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1353"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01353-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"13 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Emily J. Goddard, James M. Haughton, James E. Lucas and Sophie G. Barlow are employees of Adelphi Real World, Bollington, UK. David Wu was an employee of Johnson and Johnson Innovative Medicine and held stock in Johnson & Johnson at the time of the study. At the time of publication, David Wu was no longer an employee of Johnson and Johnson Innovative Medicine and had no other affiliation. Alexander M. Litvintchouk and Timothy P. Fitzgerald are employees of Johnson and Johnson Innovative Medicine and hold stock in Johnson & Johnson.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Using a checkbox, patients provided informed consent to take part in the survey. Data were collected in such a way that patients and physicians could not be identified directly. Data collection was undertaken in line with European Pharmaceutical Marketing Research Association (EphMRA) guidelines. Exemption from ethics approval was sought and granted from Pearl IRB. Each survey was performed in full accordance with relevant legislation at the time of data collection, including the US Health Insurance Portability and Accountability Act 1996 [], Health Information Technology for Economic and Clinical Health Act legislation [], and the Helsinki Declaration of 1964 and subsequent revisions. All authors from Johnson & Johnson Innovative Medicine United States had permission to access the Adelphi Real World PsO DSP dataset through the subscription purchased by Johnson & Johnson Innovative Medicine United States. All other authors are employees of Adelphi Real World, the dataset owner.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}